Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused promising new therapies in oncology and ...
Shares of Corbus Pharmaceuticals Holdings Inc. CRBP rallied 1.06% to $9.51 Monday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index ...
Presented data at ESMO 2025 demonstrating promising efficacy with CRB-701 in head and neck squamous cell carcinoma (HNSCC) ...
Shares of Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) were down 18.6% as of 11:50 a.m. EDT on Friday. The big tumble followed yesterday's huge gain, which stemmed from news that the ...
Combination cohort initiated following successful review of monotherapy cohort Over 100 participants dosed to-date in monotherapy cohort Priority are Head and Neck Squamous Cell Carcinoma (HNSCC) and ...
NORWOOD, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced the pricing of an ...
Corbus Pharmaceuticals Holdings Inc. has appointed Rachelle Jacques as Chair of its Board of Directors, effective May 15, 2025, succeeding Alan Holmer, who will remain on the Board. CEO Yuval Cohen ...
Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report)‘s stock had its “outperform” rating reaffirmed by research analysts at Wedbush in a note issued to investors on Wednesday,RTT News reports. They ...
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results